ArticleMolecular imaging and biology2020
Radiofluorinated GPC3-Binding Peptides for PET Imaging of Hepatocellular Carcinoma.
Article in Molecular imaging and biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 40 citations in OpenAlex.
- Glypican-3-targeted bioconjugates for hepatocellular carcinoma: design, engineering, and translational applications.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Review
- Glypican-3 targeted radiopharmaceuticals for hepatocellular carcinoma: a review of molecular platforms.EJNMMI research · 2026Review
- Glypican-3-targeted immunoPET imaging of hepatocellular carcinoma: a translational study.European journal of nuclear medicine and molecular imaging · 2026Article
- Cell surface oncofetal antigens in prostate cancer: therapeutic potential and radioligand targeting.EJNMMI research · 2026Review
- Targeting Glypican-3 in Liver Cancer: Groundbreaking Preclinical and Clinical Insights.Biomedicines · 2025Review
- PET imaging of hepatocellular carcinoma with [EJNMMI research · 2025Article
- Radiopharmaceuticals and their applications in medicine.Signal transduction and targeted therapy · 2025Review
- Gallium-68 Labeled Positron Emission Computed Tomography Tracer Targeting Glypican-3 with High Contrast for Hepatocellular Carcinoma Imaging.ACS pharmacology & translational science · 2024Article
- Glypican-3 deficiency in liver cancer upregulates MAPK/ERK pathway but decreases cell proliferation.American journal of cancer research · 2024Article
- Planted Graphene Quantum Dots for Targeted, Enhanced Tumor Imaging and Long-Term Visualization of Local Pharmacokinetics.Advanced materials (Deerfield Beach, Fla.) · 2023Article
- The expression of Ki-67 and Glypican -3 in hepatocellular carcinoma was evaluated by comparing DWI andFrontiers in oncology · 2023Article
- Circumsporozoite Protein ofPharmaceutics · 2022Article
- Molecular Imaging of Tumor Microenvironment to Assess the Effects of Locoregional Treatment for Hepatocellular Carcinoma.Hepatology communications · 2022Review
- Biomarkers and Genetic Markers of Hepatocellular Carcinoma and Cholangiocarcinoma-What Do We Already Know.Cancers · 2022Review
- Recent advances and applications of microspheres and nanoparticles in transarterial chemoembolization for hepatocellular carcinoma.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022Review
- Imaging ligands targeting glypican-3 receptor expression in hepatocellular carcinoma.American journal of nuclear medicine and molecular imaging · 2022Review
- The clinical significance of CTC enrichment by GPC3-IML and its genetic analysis in hepatocellular carcinoma.Journal of nanobiotechnology · 2021Article
- Glypican 3-Targeted Therapy in Hepatocellular Carcinoma.Cancers · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
purposeHepatocellular carcinoma (HCC) remains one of the most challenging diseases worldwide. Glypican-3 (GPC-3) is a cell surface proteoglycan that is overexpressed on the membrane of HCC cells. The purpose of this study was to develop a target-specific radiofluorinated peptide for positron emission tomography (PET) imaging of GPC3 expression in hepatocellular carcinoma. PROCEDURES: New GPC3-binding peptides (GP2076 and GP2633) were radiolabeled with F-18 using Al[
resultsAl[
conclusionThe results demonstrated that Al[
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.